Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock
Condition(s):Septic Shock; Vasodilatory ShockLast Updated:October 6, 2023Recruiting
Hide Studies Not Open or Pending
Condition(s):Septic Shock; Vasodilatory ShockLast Updated:October 6, 2023Recruiting
Condition(s):Hypertension; Hypertension, EssentialLast Updated:January 9, 2024Terminated
Condition(s):Septic Shock; Acute Kidney InjuryLast Updated:August 9, 2023Completed
Condition(s):Assisted Reproductive TechnologyLast Updated:September 21, 2022Completed
Condition(s):Chronic Kidney Disease; Urinary AngiotensinogenLast Updated:May 6, 2010Unknown status
Condition(s):Aortic StenosisLast Updated:November 15, 2022Recruiting
Condition(s):Mucopolysaccharidosis ILast Updated:March 15, 2023Completed
Condition(s):Coronavirus Disease 2019; COVID-19Last Updated:March 17, 2022Completed
Condition(s):Infection, Coronavirus; Respiratory FailureLast Updated:November 9, 2021Completed
Condition(s):Covid19; Angiotensin II Receptor Antagonist Adverse ReactionLast Updated:October 6, 2021Terminated
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.